Novo Nordisk A/S (NVO)
Estimates & Forecasts•Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
Popular:
NVO Price Targets Summary| Metric | 2023 | 2024 | 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|
| Net Income | $83.7B | $101.0B | $98.5B | $106.6B | $117.4B | $131.6B | $141.0B |
| EPS (Diluted) | $18.62 | $22.63 | $23.03 | $24.06 | $26.58 | $29.90 | $32.12 |
| YoY Growth | — | +20.7% | -2.5% | +8.3% | +10.1% | +12.1% | +7.1% |
| Net Margin | 36.0% | 34.8% | 33.1% | 33.2% | 33.2% | 33.6% | 33.7% |
USD · NVO · Proprietary Model| Metric | 2025A | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|
| Revenue | $297.2B | $321.1B | $353.2B | $391.2B | $417.9B |
| Net Income | $98.5B | $106.6B | $117.4B | $131.6B | $141.0B |
| EPS (Diluted) | $23.03 | $24.06 | $26.58 | $29.90 | $32.12 |
| Free Cash Flow | $56.7B | $91.2B | $100.8B | $112.0B | $119.9B |
Treat point estimates cautiously; use wider scenario ranges and position sizing discipline.
Quick answers to the most common questions about buying NVO stock.
Novo Nordisk A/S's projected EPS for the next fiscal year is $24.06. This estimate blends our quantitative model with Wall Street analyst consensus and carries a confidence score of 54/100. The model factors in revenue trajectory, margin path, and share buyback trends to arrive at this figure.
Our scenario-based model produces three price targets for Novo Nordisk A/S: Bear case $245, Base case $331, and Bull case $501. These targets are derived by applying the median historical P/E ratio to forward EPS estimates under each growth scenario. They are not buy/sell recommendations.
Novo Nordisk A/S's projected revenue growth for the next fiscal year is 8.1%, reaching approximately $321.1B in total revenue. Growth estimates are probability-weighted and blend analyst consensus with our CAGR extrapolation model. Outer years (FY+3, FY+4) fade toward industry median growth rates.
Accuracy depends on several measurable factors. Our model confidence score of 54/100 is computed from revenue predictability (25% weight), margin stability (20%), historical earnings beat rate (20%), data depth (15%), analyst coverage (10%), and model-consensus agreement (10%). Stable margins provide a consistent baseline. No forecast model is perfect — always cross-reference with your own analysis.
Novo Nordisk A/S's forward operating margin is estimated at 41.8% for the next fiscal year. The margin trend is currently "stable". Our model tracks margin mean-reversion patterns and adjusts for sector-specific cost dynamics. Operating leverage is a key driver of EPS growth beyond top-line revenue expansion.
The v2 model uses a multi-step process: (1) Revenue is projected via blended CAGR with probability weighting, (2) Operating and net margins follow a mean-reversion path calibrated to sector norms, (3) EPS is derived from net income divided by projected diluted shares (accounting for buyback trends), (4) For FY+1 and FY+2, estimates are blended with analyst consensus based on coverage depth, (5) Price targets apply median historical P/E to forward EPS under bear/base/bull growth scenarios. All inputs are from public filings and third-party data providers.
The bear case ($245) assumes P25 revenue growth, worst-case margins, and multiple compression. Key risks include: unexpected margin contraction, revenue deceleration below model floor, regulatory headwinds, macro deterioration, or competitive disruption. A confidence score below 60 suggests higher estimate volatility. Always size positions according to the full scenario range, not just the base case.
Our model is above Wall Street consensus with a 12.7% gap. For FY+1, analyst estimates blend with our model at 20% analyst weight. By FY+3 and FY+4, estimates are purely model-driven as analyst coverage thins out at longer horizons.